<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040261</url>
  </required_header>
  <id_info>
    <org_study_id>020231</org_study_id>
    <secondary_id>02-M-0231</secondary_id>
    <nct_id>NCT00040261</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Memantine for Major Depression</brief_title>
  <official_title>An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of the drug memantine
      for treating major depression.

      Major depression is a serious public health concern that contributes to significant morbidity
      and mortality. Despite the availability of a wide range of antidepressant drugs, a proportion
      of patients with major depression fail to respond to first-line antidepressant treatment,
      despite adequate dosage, duration, and compliance. Recent studies suggest that the
      glutamatergic system may play a role in the pathophysiology and treatment of depression.
      Memantine and other agents which reduce glutamatergic neurotransmission may represent a novel
      class of antidepressants.

      The study consists of three phases. In Phase 1, participants will be tapered off all
      psychiatric medications over a 2-week washout period. In Phase 2, participants will be
      randomly assigned to receive either memantine or placebo (an inactive pill) three times a day
      for 8 weeks. Participants who do not respond to the treatment after 8 weeks will be taken off
      the study and offered standard treatment. Weekly psychiatric evaluations will evaluate
      treatment response. During Phase 2, participants who respond well to treatment will enter
      Phase 3, a 16-week continuation phase of either memantine or placebo. Interviews will be
      conducted every other week in the first month , then monthly thereafter.

      Participants will have a physical examination, neuropsychological tests, and eye blink tests
      at baseline and at the end of the study. Pulse, blood pressure, and blood samples will be
      taken throughout the study. Participants will undergo an electrocardiogram as well as
      positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major affective disorders are common, severe, chronic and often a life-threatening illness.
      Major depression contributes to significant morbidity and mortality. Impairment in physical
      and social functioning resulting from depression can be just as severe as other chronic
      medical illnesses. Suicide is the cause of death in 10-20% of individuals with recurrent
      depressive disorders.

      Despite the availability of a wide range of antidepressant drugs, clinical trials indicate
      that 30% to 40% of patients with major depression fail to respond to first-line
      antidepressant treatment, despite adequate dosage, duration, and compliance. Thus, there is a
      clear need to develop novel and improved therapeutics for unipolar and bipolar depression.
      Recent preclinical studies suggest that antidepressants may exert delayed indirect effects on
      the glutamatergic system. Furthermore, a growing body of data suggests that mood disorders
      are associated with regional volumetric reductions, and cell loss and atrophy. It is thus
      noteworthy that lamotrigine, which, among other effects reduces glutamate release, has
      antidepressant effects, and a pilot study has suggested that NMDA antagonists may have
      antidepressant effects. Together, this data suggests that the glutamatergic system may play a
      role in the pathophysiology and treatment of depression, and that agents, which more directly
      reduce glutamatergic neurotransmission, may represent a novel class of antidepressants.

      Memantine (Akatinol memantine), an agent that is approved in Germany for dementia syndrome,
      Parkinson's disease has significant antiglutamatergic and neuroprotective properties, may
      prove to have antidepressant properties in depressed patients. In this study, we propose to
      investigate the potential efficacy of memantine, an agent which reduces glutamatergic output
      via open-channel block of the NMDA receptor-associated ion channel. Most importantly,
      memantine only blocks the channel during periods of abnormal, excessive activity, and leaves
      relatively spared normal neurotransmission. This finding is the basis for the minimal side
      effect profile displayed by memantine.

      Patients, ages 18 to 80, with a diagnosis of major depression (without psychotic features),
      will be randomized to double-blind treatment outpatient study to receive either memantine
      (5-20mg/day) or placebo for a period of 8 weeks. Following this acute period, patients who
      fully respond could enter a 16-week continuation phase. Acute efficacy will be determined by
      demonstrating a greater response rate using specified criteria. Approximately 112 patients
      with acute major depression will be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>March 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>112</enrollment>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine HCL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Subjects may be included in the study only if they meet all of the following criteria:

        Male or female subjects, 18 to 80 years of age.

        Female subjects of childbearing potential must be using a medically accepted means of
        contraception.

        Each subject must have a level of understanding sufficient to agree to all tests and
        examinations required by the protocol.

        Subjects must be considered reliable.

        Each subject must understand the nature of the study and must sign an informed consent
        document.

        Subjects must fulfill the criteria for major depression, recurrent without psychotic
        features as defined in DSM-IV based on clinical assessment and confirmed by structured
        diagnostic interview SCID-P.

        Subjects must have an initial score at Visit 1 and Visit 2 of at least 22 on the MADRS.

        Subjects must not have a decrease in the total score of MADRS of greater than 20 % during
        washout (between Visits 1 and 2).

        Current major depressive episode of at least 4 weeks duration.

        EXCLUSION CRITERIA:

        Subjects will be excluded from the study for any of the following reasons:

        Lack of response to more than 2 antidepressants (adequate dose and duration).

        Participation in a clinical trial of another investigational drug within 1 month (30 days)
        prior to study entry (Visit 1).

        Female subjects who are either pregnant or nursing.

        Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory,
        cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic,
        or hematologic disease.

        Subjects with uncorrected hypothyroidism or hyperthyroidism.

        Subjects with one or more seizures without a clear and resolved etiology.

        Documented history of hypersensitivity or intolerance to amantadine or prior treatment with
        memantine.

        DSM-IV substance abuse or dependence (except nicotine and caffeine) within the past 90
        days.

        Treatment with an injectable depot neuroleptic within less than one dosing interval between
        depot neuroleptic injections prior to Visit 2.

        Treatment with a reversible monoamine oxidase inhibitor, guanethidine, or guanadrel within
        1 week prior to Visit 2.

        Treatment with fluoxetine within 6 weeks prior to Visit 2.

        Treatment with any other concomitant medication with primarily CNS activity.

        Treatment with clozapine within 4 weeks prior to Visit 2.

        Treatment with amitriptyline (elavil) within 4 weeks prior to Visit 2 since amitriptyline
        and similar TCAs may manifest a mild NMDA receptor antagonism, as demonstrated in
        electrophysiological studies.

        Treatment with the anticonvulsants carbamazepine (tegretol, carbatrol, tegretol XR and
        similar derivatives), gabapentin (neurontin) or felbamate (felbatol) within 4 weeks prior
        to Visit 2 because these drugs may interfere with NMDA receptor function.

        Treatment with electroconvulsive therapy (ECT) within 3 months (90 days) prior to Visit 2.

        Current diagnosis of schizophrenia or other psychotic or bipolar disorder as defined in the
        DSM-IV.

        Judged clinically to be at serious suicidal risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Mental Health (NIMH)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993 Nov;150(11):1731-3.</citation>
    <PMID>8214185</PMID>
  </reference>
  <reference>
    <citation>Auer DP, PÃ¼tz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000 Feb 15;47(4):305-13.</citation>
    <PMID>10686265</PMID>
  </reference>
  <reference>
    <citation>Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study. Pharmacopsychiatry. 1988 May;21(3):144-6.</citation>
    <PMID>3406051</PMID>
  </reference>
  <verification_date>March 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2002</study_first_submitted>
  <study_first_submitted_qc>June 22, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Antiglutamatergic</keyword>
  <keyword>Neuroprotective</keyword>
  <keyword>Unipolar Depression</keyword>
  <keyword>Treatment</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Depression</keyword>
  <keyword>Glutamate</keyword>
  <keyword>Memantine</keyword>
  <keyword>Pathophysiology</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Major Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

